Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CryoLife to expand BioGlue trials in US:

This article was originally published in Clinica

Executive Summary

CryoLife intends to apply to the US FDA early next year to extend the investigational device exemption (IDE) for its BioGlue surgical adhesive to include its use in pulmonary sealing and repair, an indication for which the product is marketed in Europe. At a meeting of the Western Thoracic Surgical Association in Hawaii last month, the Atlanta, Georgia-based company said a preliminary animal study was reported of the bronchoscopic application of BioGlue as an alternative to standard lung volume reduction (LVR). LVR, which involves removing a portion of diseased lung, is used to improve respiratory function and quality of life in patients with end-stage emphysema.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT076665

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel